Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06081894 · ClinicalTrials.gov registry record · Phase 3
Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic nHCM
A Phase 3 study of Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy, sponsored by Cytokinetics.
- Active
- Registry status
- Phase 3
- Development phase
- 500
- Enrollment target
- 20
- Study locations
NCT06081894: Active Phase 3 study of Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy, sponsored by Cytokinetics.
NCT06081894 is a Phase 3 study of Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy that is active but no longer recruiting, run by Cytokinetics. The registered enrollment target is 500 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (35% lower). The trial reports 20 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06081894, a Phase 3 study of Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy, is active but no longer recruiting, sponsored by Cytokinetics.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 500 participants
- Enrollment target
- 20
- Study locations
Study Summary
This clinical trial will study the effects of aficamten (versus placebo) on the quality of life, exercise capacity, and clinical outcomes of patients with non-obstructive hypertrophic cardiomyopathy.
Primary Outcome
Effect of aficamten compared with placebo on participant health status
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Aficamten
Study Locations (20)
California
- UC San Diego Health - Sulpizio Cardiovascular Center - La Jolla
- Keck Medical Center of USC (Outpatient Clinic) - Los Angeles
- Cedars-Sinai Medical Center (Smidt Heart Institute) - Los Angeles
- UCLA Medical Center Cardiovascular Clinic - Los Angeles
- University of California San Francisco - San Francisco
- Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center - Torrance
Florida
- Holy Cross Medical Group - Cardiology Associates - Fort Lauderdale
- Investigational Drug Services, AdventHealth Orlando - Orlando
Georgia
- Emory Clinic - Atlanta
- Piedmont Heart Institute (CPET) - Fayetteville
Alabama
- University of Alabama at Birmingham - Birmingham
Connecticut
- Yale New Haven Hospital - New Haven
District of Columbia
- MedStar Washington Hospital Center - Washington D.C.
Hawaii
- The Queen's Medical Center-Punchbowl - Honolulu
Illinois
- Northwestern University - Evanston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 500 participants |
| Start Date | 2023-08-30 |
| Est. Completion | 2026-09 |
| Phase | Phase 3 |
What the registry record for NCT06081894 still lists
NCT06081894 is an interventional study that assigns participants to a tested intervention. The registered 500 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (35% lower).
The record links to 1 condition, with Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06081894 names 20 study sites across 13 states, led by California, Florida, Georgia.
Frequently Asked Questions
What is clinical trial NCT06081894 about?
NCT06081894 is a clinical study titled "Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic nHCM". This clinical trial will study the effects of aficamten (versus placebo) on the quality of life, exercise capacity, and clinical outcomes of patients with non-obstructive hypertrophic cardiomyopathy.
What is the current status of trial NCT06081894?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 500 participants. The study started on 2023-08-30. Estimated completion is 2026-09.
What conditions does trial NCT06081894 study?
This clinical trial studies the following conditions: Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy.
What interventions are being tested in trial NCT06081894?
The interventions under investigation include: Placebo (DRUG), Aficamten (DRUG).
Who is sponsoring clinical trial NCT06081894?
This trial is sponsored by Cytokinetics, which has 31 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06081894 being conducted?
This trial has 20 study locations across Alabama, California, Connecticut, District of Columbia, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06081894's enrollment target sits among peer trials
500 744th of 2000 higher than 1,227 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00001230 · 500 participants
Host Response to Infection and Treatment in Filarial Diseases
- NCT00001529 · 500 participants
Improved Methods of Cell Selection for Bone Marrow Transplant Alternatives
- NCT00697411 · 500 participants
Study of Selected X-Linked Disorders: Aicardi Syndrome
- NCT00903110 · 500 participants
Global Patient Registry to Monitor Long-term Safety and Effectiveness of Increlex® in Children and Adolescents With Severe Primary Insulin-like Growth Factor-1 Deficiency (SPIGFD).
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI